laboratory-medicine-2018-scientifictracks

6 / 14

Page 44
Notes:
conferenceseries.com
Volume 3 Diagnostic Pathology: Open Access
ISSN: 2476-2024 Laboratory Medicine 2018
June 25-26, 2018
June 25-26, 2018 | Berlin, Germany
13th International Conference on
Laboratory Medicine & Pathology
Gallbladder Adenocarcinoma; Potential Target For Anti-Her Therapy
Ghazi Zafar and Zonaira Rathore
Chughtai Lab, Pakistan
Her-2 (ErbB-2) is an oncogene frequently overexpressed in breast and gastric adenocarcinomas and anti Her-2 targeted
therapy can be given to such patients. Her-2 overexpression and role of anti Her-2 targeted therapy in cases of gallbladder
adenocarcinomas (GBAC) is still debatable. Scoring protocols for Her-2 expression in breast and gastric carcinomas are
standardized, however not for carcinomas arising in other body organs like gallbladder. This study is conducted to evaluate
expression of Her-2 in patients with GBAC which may benefit from targeted therapy. It is a cross-sectional study conducted
on patients with GBAC (n=43; 34 women and 9 men). An automated immunohistochemical technique was used with an
anti-ErbB2 antibody. Scoring was conducted according to the CAP (College of American Pathologists) criteria for breast
cancer, as well as for gastric and gastroesophageal junction carcinomas. When the scoring protocol for breast carcinomas was
used, positive Her-2 staining was observed in 11/43 (25.6%). Out of 11 positive cases, 5 cases (11.6%) were unequivocally
positive (3+) and 6 (13.9%) showed equivocal staining. According to the gastric and gastroesophageal junction carcinomas
protocol, positive Her-2 staining was observed in 16/43 (37.2%). Out of 16 positive cases, 11 (25.5%) were unequivocally
positive (3+) and 5 (11.6%) showed equivocal staining. This study indicates that significant number of GBAC cases show Her-2
overexpression when either of the two documented protocols is used. This subgroup may benefit from inhibitors of the Her-2
pathway. Standardization of scoring protocol for Her-2 expression in GBAC is needed to better evaluate predictive potential of
Her-2 for treatment of these tumors.
Biography
Ghazi Zafar completed his MBBS from University of Health Sciences in 2013. He is currently pursuing his Postgraduation Residency in Histopathology from
Chughtai Lab, Pakistan.
Ghazi Zafar et al., Diagn Pathol Open 2018, Volume 3
DOI: 10.4172/2476-2024-C1-002